Gilead’s current lenacapavir patent is what makes Dr Reddy’s Laboratories’ formulation tentative.
|Articles|July 1, 2010
Drug Topics, Digital Edition, July 2010
Vitamins & Supplements : Why Pharmacists' recommendations matter Starting a pharmacy service business ASHP issues guidelines on remote order processing Associations weigh in on e-prescribing rule
Advertisement
Advertisement
Related to this article
Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Advertisement
Advertisement
Trending on Drug Topics
1
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
2
FDA Grants Tentative Approval for First Generic Lenacapavir
3
ACCESS to Pharmacy Care Model Lets Pharmacists Bill for Chronic Care
4
Missouri Challenges Lilly’s 340B Data Policy: What Stakeholders Should Know
5